

Reference:	FOI.19803.26
Subject:	Ophthalmology's use of Kenalog
Date of Request:	2 March 2026

Requested:

Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department:

1. The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years.
2. A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post-operative inflammation), if available.
3. Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology.
4. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period.
5. The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held.
6. Whether Kenalog (triamcinolone) is listed on the Trust's formulary for Ophthalmology, and if so, any restrictions or criteria for its use.
7. As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to:
 - a. whether the Ophthalmology department is continuing to use existing stock,
 - b. any plans or decisions to discontinue its use, and
 - c. any identified or recommended alternative treatments.

Please provide the information in electronic format.

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of Kenalog vials administered by Ophthalmology during the 2023/24 and 2024/25 financial years and 1 April 2025 to 17 March 2026.

Time period	Number
2023/2024	10
2024/2025	0
1 April 2025 to 17 March 2026	0

2. The UHB does not hold this information as the conditions treated are not recorded.
3. The UHB does not have any current guidelines on the use of Kenalog in Ophthalmology.

4. The UHB confirms zero (0) incidents have been captured on the Datix incident reporting system relating to the use of Kenalog in Ophthalmology, during the 2023/24, 2024/25 and 2025/26 financial years.
5. The UHB provides, within the table below, the number of Kenalog vials issued by Pharmacy to Ophthalmology during the 2023/24 and 2024/25 financial years and 1 April 2025 to 17 March 2026.

Financial Year	Number of vials issued
2023/2024	10
2024/2025	0
1 April 2025 to 17 March 2026	0

6. Kenalog is not listed on the UHB's formulary.
- 7a. The UHB confirms it has no Kenalog left in stock.
- 7b. The UHB confirms it has discontinued the use of Kenalog.
- 7c. The UHB is using Intracinol as the alternative to Kenalog.